Obstetric and Perinatal Outcomes in Pregnant Women with Lupus: Retrospective Study in a Portuguese Tertiary Center

Keywords

lupus erythematosus - pregnancy - pregnancy outcome - neonatal systemic lupus erythematosus - Resumo

Palavras-chave

lúpus eritematoso - gravidez - resultado da gravidez - lúpus eritematoso sistêmico neonatal

Introduction

Systemic lupus erythematosus (SLE) is a chronic, systemic, and immune-mediated disease that mostly affects women of childbearing age.[1]

In the last years, there has been an increase in the overall survival rate, a higher number of pregnancies, and an improvement in obstetric and perinatal outcomes. This was due to greater access to preconception counseling and multidisciplinary surveillance throughout pregnancy, as well as better perinatal care.[2]

However, this disease carries a significant risk of obstetric and perinatal complications, the pathogenesis of which is mainly related to uteroplacental insufficiency, the inflammatory state underlying the disease, and the possibility of maternal immunoglobulin G (IgG) autoantibodies crossing the placental circulation and binding to fetal tissues.[3] [4]

Regarding the obstetric complications, there is an increased risk of abortion, preterm birth, fetal death; the hypertensive complications include preeclampsia (PE), eclampsia (E) and/or hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome; other complications include gestational diabetes, fetal growth restriction (FGR), a higher rate of infections, thromboembolic complications, cesarean sections, and postpartum complications, including infection, hemorrhage, and lupus flares.[5] [6] [7]

Many predictors of complications and adverse outcomes have been described in the literature, namely: lupus nephritis, damage to other organs (lung, heart, central nervous system), interruption of the medical treatment, active disease in the six months before conception, antiphospholipid syndrome (APS) or the presence of persistent antiphospholipid antibodies, hypocomplementemia, thrombocytopenia, and high levels of anti-double stranded DNA (anti-dsDNA), anti-Sjögren's-syndrome-related antigen A (anti-SSA/Ro), and anti-Sjögren's-syndrome-related antigen B (anti-SSB/La) antibodies.[8] [9]

Regarding newborns (NBs) of mothers with SLE, there is an increased risk of several complications, namely: prematurity, low birth weight. and neonatal lupus.[10] [11] [12]

The present study aimed to assess the obstetric and perinatal outcomes of pregnant women with SLE.

Materials and Methods

We conducted a retrospective observational study, in which we evaluated pregnant women diagnosed with SLE included in the database of the Materno-Fetal Medicine Clinic of our institution. We included women diagnosed with lupus who had been surveilled in the Obstetrics Department between January 2013 and July 2018. The study included 52 women, totaling 59 pregnancies and 52 NBs. We excluded pregnant women whose birth took place at another institution, as well as women and/or NBs whose clinical files were incomplete or unavailable for consultation.

We collected data regarding sociodemographic features and data relating to the pre-conception period, pregnancy, childbirth, postpartum and NB, and performed a descriptive analysis of the variables using Microsoft Excel 2013 (Microsoft Corp., Redmond, WA, United States) and IBM SPSS Statistics for Windows (IBM Corp., Armonk, NY, United States), version 25.0, with a confidence interval of 95% (95%CI) and a statistical significance level of 0.05. Early abortion was classified as a spontaneous pregnancy loss up to 11 weeks and 6 days; late abortion, as a pregnancy loss between 12 and 21 weeks and 6 days; fetal death, as an intrauterine death from 22 weeks onwards; and preterm delivery, as those occurring between 22 and 36 weeks + 6 days. Preeclampsia was defined by hypertension and proteinuria and/or organ dysfunction after 20 weeks, in a previously normotensive woman, and gestational hypertension referred to hypertension without proteinuria after 20 weeks, in a previously normotensive woman. Fetal growth restriction was defined through an ultrasound estimate of fetal weight below the 3rd percentile or an ultrasound estimate of fetal weight below the 10th percentile for gestational age along with Doppler changes. Small for gestational age (SGA) was defined as an estimate of fetal weight below the 10th percentile for gestational age without Doppler changes, and large for gestational age (LGA) referred to fetal weight above the 90th percentile for gestational age. We also defined flare as an increase in lupus activity in a patient with inactive disease, and postpartum complications, as hypertensive, hemorrhagic, infectious complications, and postpartum anemia.

The present study was approved by the Ethics Committee of the hospital where it was performed, and international ethical standards were followed.

Results

Starting with the demographic features ([Table 1]), the mean age of the pregnant women was of 33.5 ± 5.6 (range: 18 to 46) years, 92% were Caucasian, and 8% were of African origin. Regarding parity and previous obstetric history, most women were multiparous (53%), and there was a history of prior abortion in 25% of the cases, half of which were associated with APS; in 7% of the cases, there was a history of fetal death, half of them associated with APS. As far as lupus is concerned, the mean duration of the disease at the beginning of the obstetric follow-up in the Materno-Fetal Medicine Clinic was of 10.0 ± 6.3 (range: 0 to 25) years. The most frequent lupus manifestations were cutaneous, articular, immunological, and hematological ([Fig. 1]). We registered a thromboembolic history in 14% of the cases and other rheumatologic diseases in 10%.

Fig. 1 Preconceptional manifestations of lupus, relative frequency (n = 59).

Table 1 Sociodemographic, clinical, and laboratory features of the study sample

Sociodemographic, clinical and laboratory features	Frequency (n)	%
Sociodemographic features
Caucasian race	54	92
African origin	5	8
Age: 18–29 years	18	30
Age: 30–39 years	34	58
Age: 40–46 years	7	12
Nulliparous	28	47
Multiparous	31	53
Duration of the disease < 10 years	24	41
Duration of the disease ≥ 10 years	35	59
Clinical features
Active disease in the preconception period	6	10
Lupus nephritis	6	10
Antiphospholipid syndrome	15	25
Hypertension	6	10
Secondary to lupus nephritis	4	7
Primary	2	3
Laboratory features – analytical alterations
Anemia	8	14
Leukopenia	3	5
Lymphopenia	3	5
Neutropenia	1	2
Thrombocytopenia	4	7
Hypergammaglobulinemia	1	2
Hypocomplementemia	8	14
Proteinuria	10	17
Not applicable*	3	5
Laboratory features – antibodies
Antiphospholipid antibodies	17	29
Anti-ribonucleoprotein	9	15
Antinuclear antibodies	37	63
Anti-double stranded DNA	15	25
Anti-Sjögren's-syndrome-related antigen A	18	31
Anti-Sjögren's-syndrome-related antigen B	8	14
Not applicable*	3	5

Note: *Not applicable due to early abortion, and no analytical evaluation was performed (n = 59).

Before getting pregnant, most women in the sample (76%) did not undergo preconception consultation. Most were singleton pregnancies, but we registered one case of twin pregnancy. Regarding the clinical risk factors ([Table 1]), most pregnancies started with the disease in an inactive state or in remission (90%). We observed lupus nephritis in the current pregnancy in 10% of the cases, APS in 25%, and hypertension in 10%, which was secondary to lupus nephritis in most cases (67%). Considering the laboratory findings ([Table 1]), anemia occurred in 14% of the pregnancies, thrombocytopenia, in 7%, hypocomplementemia, in 14%, and proteinuria, in 17%. Regarding the antibody profile, there were positive antiphospholipid antibodies in 29% of the cases, positive anti-ribonucleoprotein (anti-RNP) antibodies in 15%, positive anti-dsDNA in 25%, and positive antinuclear antibodies (ANAs) in 63%, which were anti-SSA in 31% of the cases and anti-SSB in 14% of te cases, the latter always occurring concomitantly with the presence of anti-SSA. We registered some complications of the pregnancy ([Table 2]), namely hypertensive complications, flares, growing disturbances, and abortive outcome; hypertensive complications were recorded in 10% of the cases, with 3% corresponding to PE and 7%, to gestational hypertension; 25% of the cases had a lupus flare, with the most frequent manifestations being skin rash, joint pain, vasculitis, and worsening of the proteinuria; FGR occurred in 12% of the pregnancies, and we recorded early abortion in 5% of the cases, late abortion in 3%, and fetal death in 2% (n = 1). The case of fetal death occurred at 30 weeks, in a fetus with trisomy 18. Delivery was uneventful in most cases. The mean gestational age at delivery was of 38 weeks and 4 days ± 10 days, with preterm delivery occurring in 10% of the cases. We registered normal vaginal delivery in 32% of the cases, delivery assisted by vacuum extraction in 9%, forceps in 9%, forceps after failed vacuum extraction in 6%, and cesarean section in 44% of the cases (planned in 25% and intrapartum in 19% of the cases). The immediate postpartum period was marked by complications in 20% of the cases ([Table 3]): de novo hypertension in 2%, anemia in 10%, postpartum hemorrhage in 2%, and infection in 7%. We did not observe thromboembolic complications. In the postpartum period, we recorded flares in 2% of the cases, with hematological manifestations.

Table 2 Complications during pregnancy and the postpartum period (n = 59)

	Frequency (n)	%
Complications of pregnancy
Fetal growth restriction	7	12
Gestational diabetes	6	10
Gestational hypertension	4	7
Early abortion	3	5
Preeclampsia	2	3
Late abortion	2	3
Respiratory infection	2	3
Pregnancy cholestasis	2	3
Thromboembolic events	1	2
Fetal death	1	2
Complications of the postpartum period
Hypertensive (de novo hypertension)	1	2
Anemia	6	10
Hemorrhage	1	2
Infection	4	7
Respiratory	2	3
Urinary	1	2
Surgical wound	1	2

Table 3 Therapy administered in the preconception period, throughout pregnancy, and the postpartum period (n = 59)

Treatment	Preconception: n (%)	Pregnancy: n (%)	Postpartum: n (%)
None	11 (19%)	4 (7%)	4 (7%)
Hydroxychloroquine	47 (80%)	50 (85%)	50 (85%)
Prednisolone	33 (56%)	33 (56%)	34 (58%)
Azathioprine	13 (22%)	15 (25%)	15 (25%)
Tacrolimus	0	2 (3%)	2 (3%)
Acetylsalicylic acid	23 (39%)	34 (58%)	34 (58%)
Enoxaparin	10 (17%)	19 (32%)	18 (31%)

As far as treatment is concerned ([Table 3]), 19% of the pregnancies occurred in women who were not undergoing any type of treatment. In total, 80% of the medicated women were taking hydroxychloroquine (HCQ), 56% were under corticosteroid therapy with prednisolone, 22% were medicated with azathioprine, 39% were taking acetylsalicylic acid (ASA), and 17%, enoxaparin. During pregnancy, most women were medicated with HCQ (85%) and/or prednisolone (56%), and 25%, with azathioprine, and 3% with tacrolimus. Most pregnant women took ASA (58%), and 32% took enoxaparin. In the postpartum period, therapy was similar to that recorded during pregnancy.

We had a sample of 52 NBs, and 59% of them were female. The mean birth weight was of 2,968 ± 462 g (range: 1,920 g to 3,845 g), with 17% of the cases being SGA. We did not register any LGA NBs. In 90% of the cases, the NBs were hospitalized with their mothers, and 10% needed special neonatal care. Most NBs had no clinical or laboratory alterations. Upon physical examination ([Table 4]), 31% had jaundice, 2% had exanthema, and 8% had alterations in the primitive reflexes; there were no other relevant changes. Regarding the NBs who underwent analytical evaluation ([Table 4]), 5% had anemia, 2% had thrombocytopenia, 48% had hyperbilirubinemia, 5% had an increase in gamma-glutamyl-transferase, and 13% had hypoglycemia; the autoimmune profile was determined in a minority of NBs. An electrocardiogram (ECG) was requested in 71% of the NBs, with no alterations in the atrioventricular conduction.

Table 4 Alterations on the physical and laboratory examinations of the newborns

	Frequency (n)	%
Physical examination
Exanthema	1	2a
Jaundice	16	31a
Heart murmurs	1	2a
Respiratory distress syndrome	1	2a
Primitive reflex changes	4	8a
Laboratory findings
Blood count	43	83a
Anemia	2	5 b
Leucopenia	8	19b
Platelet count	42	81a
Thrombocytopenia	1	2c
Liver profile	21	40a
Increased transaminases	3	14d
Hyperbilirubinemia	10	48d
GGT increase	1	5d
Antibody profile	5	10a
Positive antibodies	3	60e
Antinuclear antibodies	3	75f
Anti-double stranded DNA	1	50c
Anti-Sjögren's-syndrome-related antigen A	1	20e
Anti-Sjögren's-syndrome-related antigen B	1	20e
Complement dosage	1	2a
Hypocomplementemia	1	100g
Blood glucose measurement	23	44a
Hypoglycemia	3	13h

Notes: ^an = 52; ^bn = 43; ^cn = 2; ^dn = 21; ^en = 5; ^fn = 4; ^gn = 1; ^hn = 23.

Discussion

In the series herein presented, the percentage of pregnancy loss was of 8%. This value is below the average found in the literature, with values in the order of 20% to 30%, probably related to the lack of records of early abortions.[12] [13] There are some identified risk factors for abortion, namely: a history of abortion, proteinuria, APS, AAF, thrombocytopenia, hypocomplementemia, positive anti-dsDNA antibodies, HTA, exacerbations, previous lupus nephritis, PE/E, active disease in the six months before conception, and inaugural SLE in pregnancy.[7] [8] [14] [15] [16]

Of the 5 cases of women with abortion that we recorded, 4 had concomitant APS, and this condition was registered in 25% of the study sample. The association between APS and adverse obstetric outcomes has been described, including miscarriages, FGR, PPT, and hypertensive disorders in pregnancy.[8] [14] [15] [16]

Recent data report an European rate of prematurity ranging from 5% to 9%, which contrasts with the 30% to 33% reported in the literature regarding the global population of NBs whose mothers have SLE.[17] [18] [19] In the sample of the present study, we found 10% of preterm deliveries, a percentage substantially lower than the values reported in the literature concerning the global population with SLE. We highlight that all the preterm NBs in the present series were late preterm.

Several studies[5] [7] [8] [14] [20] [21] report an association of preterm delivery with some risk factors, namely: high disease activity at conception, positive antiphospholipid antibodies, APS, flares, obstetric history of abortion, thromboembolic complications, previous lupus nephritis, hypertension, PE/E, hypocomplementemia, proteinuria, positive anti-dsDNA antibodies, thyroid disease, and prednisolone treatment dose higher than 15 mg/day.[5] [7] [8] [14] [20] [21]

Fetal growth restriction occurred in 12% of the cases, which is similar to the values already described, which range from 6% to 30%.[5] [12] [13] [22] The literature describes a relationship between FGR and some predictors, namely: APS, positive antiphospholipid antibodies, hypertension, or lupus nephritis.[9]

As for PE, it occurred in 2 cases (3%), 1 of which overlapped with chronic hypertension. This percentage is in the range of incidence referred in different studies, which is of 3% to 30%, and is also similar to the percentage found in the population of pregnant women without SLE (∼ 5%).[5] [12] [13] [18] [22] [23] There is a well-described relationship between PE and the existence of lupus nephritis,[14] [24] as well as with some other risk factors, such as positive antiphospholipid antibodies, APS, hypocomplementemia, and positive anti-RNP or anti-dsDNA antibodies.[5] [8] [18] [24] [25] [26]

In about a quarter of the pregnancies (25%), SLE flares occurred, the most frequent manifestations being cutaneous and articular, which is in agreement with the literature.[9] [24]

It is known that active disease in the preconception period is a predictor of the occurrence of flares. In the present study, it is possible that the absence of disease activity before pregnancy, which was observed in most patients (90%), contributed to the low rate of flares (∼ 25%), which is comparable to the rates reported in other studies, with an incidence ranging from 10% to 33%.[18] [27] [28]

Most of the sample of the present study had a mild form of the disease, which was probably the main contributing factor to the considerably favorable results. On the other hand, most patients (85%) received HCQ as part of their treatment during pregnancy, which may have also contributed to the good outcomes obtained.

Hydroxychloroquine was identified as a protective factor against adverse outcomes, especially flares.[29] The literature also associates this drug with possible preventive effects regarding to congenital atrioventricular block, and some studies also report a therapeutic effect on this condition, as well as effects in the reduction if prematurity, FGR and SGA.[8] [30] [31] In the present study, we did not identify changes in atrioventricular conduction in any of the NBs in the sample.

Flares in the immediate postpartum period were much less significant, with only one case, which occurred in a patient with a record of exacerbation during pregnancy. Some studies have demonstrated that patients with flares during pregnancy have an increased risk of developing postpartum exacerbations.[18]

The rate of SGA NBs in the general population is of ∼ 10%.[19] In the present study, we found that 17% of the NBs were SGA, which is in agreement with the results obtained in previous studies (10% to 30%).[10] There are variables associated with SGA NBs, including African origin, prematurity, hypertensive complications or lupus nephritis.[24] [26] [32]

Neonatal lupus is a rare syndrome, which occurs in 1% to 2% of NBs to mothers with anti-SSA and/or anti-SSB autoantibodies, manifesting more frequently by cardiac, cutaneous, hematological, and hepatic alterations. In the present study, none of the documented alterations in the NB was presumably associated with an autoimmune etiology; as an example, the high incidence of jaundice can be related to hemolytic disease of the NB. However, it should be noted that the manifestations of neonatal lupus can mimic many other neonatal pathologies, possibly appearing at a later stage.

The percentage of NBs in need of special neonatal care was similar to the percentage of general NBs in our institution with this need (10% versus 11%).

The present study incorporates the limitations inherent to a small sample resulting from a retrospective analysis of a single center and for a limited period of time. Other limitations are related to the exclusive access to the records of the NBs during the period of hospitalization, and we did not consult records related to subsequent hospitalizations, follow-up appointments or admissions to the emergency service, which would be of interest, given that the manifestations related to neonatal complications in NBs to mothers with SLE may appear during the first weeks/months of life.[4] The fact that pregnant women who gave birth outside our institution were not included led to the exclusion of part of the pregnancies in follow-up, which constitutes another limitation of the present study, as well as the fact that the absence of electronic clinical records during the study period led to the exclusion of pregnant women and NBs whose handwritten files were not available for consultation or had incomplete data.

Conclusion

In conclusion, we found that most women in this sample had good obstetric and neonatal outcomes, with low rates of abortion, preterm birth, and PE. The most frequent complications were FGR and SGA NBs, but even so, with rates similar to those obtained in other series. The fact that most women had a mild form of the disease and were taking HCQ during pregnancy may have contributed to the good obstetric and neonatal outcomes observed. Thus, although most pregnant women with SLE have favorable obstetric and perinatal outcomes, these women continue to represent a risk group for obstetric complications. To improve obstetric and perinatal outcomes, it is essential to plan the pregnancy during a remission phase of the disease, so that adequate multidisciplinary surveillance of the pregnancy and optimal treatment of the disease can be performed, as well as to plan the delivery in a differentiated perinatal center.

• References

• 1 Berghella V. Maternal-Fetal Evidence Based Guidelines. Third edition. Boca Raton: CRC Press, Taylor & Francis Group; 2017. . 246–253
• 2 Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol 2005; 32 (09) 1709-1712
• 3 Ostensen M, Clowse M. Pathogenesis of pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25 (05) 591-596
• 4 Hwang JK, Park HK, Sung YK, Hoh JK, Lee HJ. Maternal outcomes and follow-up of preterm and term neonates born to mothers with systemic lupus erythematosus. J Matern Fetal Neonatal Med 2018; 31 (01) 7-13
• 5 Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008; 199 (02) 127.e1-127.e6
• 6 Wallenius M, Salvesen KÅ, Daltveit AK, Skomsvoll JF. Systemic lupus erythematosus and outcomes in first and subsequent births based on data from a national birth registry. Arthritis Care Res (Hoboken) 2014; 66 (11) 1718-1724
• 7 Bundhun PK, Soogund MZ, Huang F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016. J Autoimmun 2017; 79: 17-27
• 8 Borella E, Lojacono A, Gatto M. , Andreoli L, Taglietti M, Iaccarino L, et al. Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunol Res 2014; 60 (2-3): 170-176
• 9 Fischer-Betz R, Specker C. Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. Best Pract Res Clin Rheumatol 2017; 31 (03) 397-414
• 10 Kim SY, Lee JH. Prognosis of neonates in pregnant women with systemic lupus erythematosus. Yonsei Med J 2008; 49 (04) 515-520
• 11 Iijima S. Fetal and neonatal involvement in maternal rheumatologic disease. J Matern Fetal Neonatal Med 2018; 31 (15) 2079-2085
• 12 Abdwani R, Al Shaqsi L, Al-Zakwani I. Neonatal and Obstetrical Outcomes of Pregnancies in Systemic Lupus Erythematosus. Oman Med J 2018; 33 (01) 15-21
• 13 Teh CL, Wan SA, Cheong YK, Ling GR. Systemic lupus erythematosus pregnancies: ten-year data from a single centre in Malaysia. Lupus 2017; 26 (02) 218-223
• 14 Deguchi M, Maesawa Y, Kubota S, Morizane M, Tanimura K, Ebina Y, Yamada H. Factors associated with adverse pregnancy outcomes in women with systematic lupus erythematosus. J Reprod Immunol 2018; 125: 39-44
• 15 Clowse ME, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006; 107 (2 Pt 1): 293-299
• 16 Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 2012; 8 (05) 439-453
• 17 Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D. et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health 2019; 7 (01) e37-e46
• 18 Kroese SJ, Abheiden CNH, Blomjous BS, van Laar JM, Derksen RWHM, Bultink IEM. et al. Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study. J Immunol Res 2017; 2017: 8245879
• 19 Nili F, McLeod L, O'Connell C, Sutton E, McMillan D. Maternal and neonatal outcomes in pregnancies complicated by systemic lupus erythematosus: a population-based study. J Obstet Gynaecol Can 2013; 35 (04) 323-328
• 20 Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52 (02) 514-521
• 21 Moroni G, Doria A, Giglio E. , Tani C, Zen M, Strigini F, et al. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun 2016; 74: 6-12
• 22 Bermas BL, Smith NA. . Pregnancy in women with systemic lupus erythematosus [Internet]. UpToDate: [updated 2021 Oct; cited 2021 Nov 28]. Available from: https://www.uptodate.com/contents/pregnancy-in-women-with-systemic-lupus-erythematosus#H452135627
• 23 Chen D, Lao M, Zhang J, Zhan Y, Li W, Cai X, Zhan Z. Fetal and Maternal Outcomes of Planned Pregnancy in Patients with Systemic Lupus Erythematosus: A Retrospective Multicenter Study. J Immunol Res 2018; 2018: 2413637
• 24 Diniz-da-Costa T, Centeno M, Pinto L, Marques A, Mendes-Graça L. Lupus eritematoso sistémico e gravidez. [Systemic lupus erythematosus and pregnancy] Acta Med Port 2012; 25 (06) 448-453
• 25 Moroni G, Doria A, Giglio E, Imbasciati E, Tani C, Zen M. et al. Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun 2016; 74: 194-200
• 26 Lateef A, Petri M. Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol 2012; 8 (12) 710-718
• 27 Cortés-Hernández J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002; 41 (06) 643-650
• 28 Lê Huong D, Wechsler B, Vauthier-Brouzes D, Seebacher J, Lefèbvre G, Blétry O, Darbois Y. et al. Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies. Br J Rheumatol 1997; 36 (07) 772-777
• 29 Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54 (11) 3640-3647
• 30 Yamamoto Y, Aoki S. Systemic lupus erythematosus: strategies to improve pregnancy outcomes. Int J Womens Health 2016; 8: 265-272
• 31 Leroux M, Desveaux C, Parcevaux M, Julliac B, Gouyon JB, Dallay D. et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015; 24 (13) 1384-1391
• 32 Clowse ME, Grotegut C. Racial and Ethnic Disparities in the Pregnancies of Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2016; 68 (10) 1567-1572